Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART?

Gross R, Bilker WB, Wang H, Chapman J.

HIV Clin Trials. 2008 May-Jun;9(3):202-6. doi: 10.1310/hct0903-202.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].

Domingo P, Ribera E.

Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:20-9. doi: 10.1016/S0213-005X(13)70139-3. Review. Spanish.

PMID:
24252530
4.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
5.

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.

Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B.

Int J Infect Dis. 2014 Aug;25:130-5. doi: 10.1016/j.ijid.2014.04.020. Epub 2014 Jun 6. Review.

6.

Efavirenz: a decade of clinical experience in the treatment of HIV.

Maggiolo F.

J Antimicrob Chemother. 2009 Nov;64(5):910-28. doi: 10.1093/jac/dkp334. Epub 2009 Sep 18. Review.

Supplemental Content

Support Center